Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ESLA | Estrella Biopharma Inc

Financial | Shell Companies | USA | NASD

Index	-	P/E	-	EPS (ttm)	-0.18	Insider Own	61.20%	Shs Outstand	2.33M	Perf Week	-72.99%
Market Cap	6.40M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.84M	Perf Month	-76.81%
Income	-0.63M	PEG	-	EPS next Q	-	Inst Own	34.82%	Short Float / Ratio	1.28% / 0.02	Perf Quarter	-72.91%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	1.51%	Short Interest	0.01M	Perf Half Y	-70.91%
Book/sh	2.97	P/B	0.99	EPS next Y	-	ROA	-2.28%	Target Price	-	Perf Year	-70.20%
Cash/sh	0.01	P/C	213.38	EPS next 5Y	-	ROE	-2.51%	52W Range	2.79 - 33.00	Perf YTD	-71.33%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-9.16%	52W High	-91.06%	Beta	0.05
Dividend %	-	Quick Ratio	0.09	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.64%	ATR	3.25
Employees	-	Current Ratio	0.09	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	36.93	Volatility	43.62% 34.67%
Optionable	No	Debt/Eq	0.13	EPS Q/Q	46.99%	Profit Margin	-	Rel Volume	1.21	Prev Close	2.85
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	495.93K	Price	2.95
Recom	-	SMA20	-70.43%	SMA50	-69.28%	SMA200	-70.96%	Volume	598,928	Change	3.51%

Sep-29-23 10:34AM	TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination (PR Newswire) -6.22%
Sep-18-23 05:00PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire) +34.29%
Aug-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-12-23 07:00AM	TradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash (PR Newswire)

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Wilmington, DE.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ESLA | Estrella Biopharma Inc

Upgrade your FINVIZ experience